When Insilico Medicine announced that its generative AI platform had "discovered" a promising drug candidate for pulmonary fibrosis, the company's celebratory framing masked a growing crisis in how the biotech industry credits—and patents—AI-assisted discoveries. Insilico's press release suggested the AI system deserved primary attribution, a claim that reverberated through pharmaceutical research circles and prompted sharp pushback from academic scientists who questioned whether algorithmic pattern-matching constituted genuine invention. The distinction matters enormously: patents, which form the legal foundation for drug development funding and commercialization rights, require clear human inventorship under current U.S. law. The U.S. Patent and Trademark Office has consistently rejected patent applications listing AI systems as inventors, creating a legal gray zone for companies like Insilico that increasingly rely on machine learning to narrow compound libraries from billions to thousands of candidates. These molecules still require human chemists to synthesize, test, and validate them—but the narrative of who "discovered" them has become muddled and commercially consequential.
The scientific community has begun to organize resistance to corporate AI attribution claims. Nature and Science journals now require explicit disclosure of AI involvement in research, yet lack binding guidance on how to weight machine contributions against human expertise. More critically, the FDA has begun drafting informal guidance—expected by mid-2025—on how AI-discovered compounds will be evaluated in drug approval dossiers, focusing on reproducibility and transparency rather than attribution per se. Meanwhile, the Biotechnology Industry Organization launched a working group in Q4 2024 to develop industry standards for AI credit, though no binding framework yet exists. A concrete liability dispute has already surfaced: in 2024, a former Insilico researcher filed comments with the USPTO arguing that misattribution of AI discoveries to machines rather than human teams obscures accountability chains critical for regulatory review, potentially creating liability exposure if safety issues emerge post-approval. The researcher contended that when corporations claim AI discovered compounds, they sidestep documenting the specific human decisions—target selection, parameter tuning, validation protocols—that shaped outcomes. This argument has gained traction among FDA reviewers concerned that inflated AI credit claims could mask human judgment failures during clinical trials.
The stakes are accelerating sharply because drug discovery is one of AI's few commercially proven applications, attracting billions in venture capital and corporate R&D budgets. If attribution rules aren't clarified within 12-24 months, two cascading problems emerge. First, patent disputes will multiply: investors funding AI biotech startups face mounting uncertainty about whether their IP portfolios will survive USPTO challenges, potentially freezing capital flows to the sector. Second, regulatory transparency erodes: FDA reviewers cannot properly assess risk if human decision-makers are obscured behind inflated AI credit, potentially accelerating approval of inadequately scrutinized compounds. The European Union's AI Act already mandates high-risk AI transparency requirements, and the EMA (European Medicines Agency) is developing parallel guidance, creating transatlantic regulatory divergence that will force multinational biotech firms to maintain dual documentation standards. Without harmonized rules governing how AI contribution is documented and credited, the industry faces either a costly reinvention of its discovery-to-patent workflow or regulatory rejection of compounds developed under ambiguous attribution frameworks. The window to establish these standards before AI-discovered drugs reach Phase 3 trials—where investment is heaviest and regulatory stakes highest—is closing rapidly.